Reimagining the Future of Biologics
We’re Making High-Quality Biologics More Accessible
Fresenius Kabi has been supplying oncology medicines in the United States for more than a quarter of a century, and today we are building on our expansive portfolio and deep experience by developing a range of biosimilar medicines for oncology as well as immunology.
We have already launched biosimilars in Europe and Canada, turning the promise of effective and affordable biologic therapies into reality for many patients.
And now we are poised to bring high-quality biosimilars to the United States.
That’s Why We’re BioSpecialized
Fresenius Kabi is committed to the future of biologics, and we’re going beyond supplying medicines. Our entire approach is BioSpecialized. From the collaborative way we work with health care professionals and patients, to how we manufacture and deliver our products.
Fresenius was founded in 1912 and has been supporting patient care ever since. We’re committed to caregivers and the patients they serve. Today, we have hundreds of BioSpecialized team members in the U.S. and around the world providing dedicated biosimilars support and guidance. We are here to help you and your patients.
You can also count on our experienced supply chain professionals. We take efforts to meet supply demands, even during crises. During the COVID-19 pandemic we increased supply of dozens of lifesaving medicines to meet market fluctuations. After devastating hurricanes impacted our competitors, the FDA awarded us a Drug Shortage Assistance Award for our ability to deliver when others could not.
And we are continuing to employ advanced research and manufacturing technologies to make drug development and production more efficient.
Above all, we are committed to making high-quality health care affordable and accessible to more patients coping with critical and chronic diseases.
Follow our BioSpecialized journey here.